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Abstract
Cardiovascular disease is the leading cause of death worldwide. The role of cardiac 
markers in the diagnosis, risk stratification, and treatment of patients with chest pain 
is vital. Patients with elevated cardiac troponin levels but negative CK-MB who were 
formerly diagnosed with unstable angina or minor myocardial injury are now reclas-
sified as non–ST-segment elevation MI (NSTEMI) even in the absence of diagnostic 
ECG changes. CK-MB is both a sensitive and specific marker for myocardial infarc-
tion. Cardiac troponin T is a cardio-specific, highly sensitive marker for myocardial 
damage. Cardiac troponin I is a contractile protein exclusively present in the cardiac 
muscle. The absolute cardiospecificity of cTnI allows the diagnosis of myocardial 
infarction distinct from muscle lesions and non-cardiac surgery. In 2000, the European 
Society of Cardiology and the American College of Cardiology redefined AMI with 
a particular advocacy on troponin. The 2002/2007 American College of Cardiology 
(ACC) and the American Heart Association (AHA) Guideline Update for the manage-
ment of these patients strongly recommend to include cTnI. Specifically, with rare 
exception, the diagnosis cannot be made in the absence of elevated biomarkers of 
cardiac injury.
Keywords: acute myocardial infarction, unstable angina, CK-MB, cardiac troponin T, 
cardiac troponin I
1. Introduction
Cardiovascular disease is the foremost cause of death globally, accounting for an estimated 
16.7 million deaths per year [1]. The prevalence of coronary artery disease (CAD) varies 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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between different geographical locations around the world. For example among South Asian 
populations, Pakistani people have the highest known rate of CAD. According to careful 
estimates nearly 100,000 individuals suffered from acute myocardial infarction (AMI) in 
Pakistan, in 2002 [2].
Acute MI is commonly presented with chest pain or discomfort, weakness, sweating, nausea, 
vomiting, and arrhythmias, sometimes loss of consciousness and syncope. It occurs with the 
sudden interruption of coronary blood flow and it is a life-threatening medical emergency 
which requires quick management [3, 4].
2. Pathophysiology
Myocardial ischemia may occur either from increased demand of oxygen by the myocar-
dium, or decreased oxygen supply to the myocardium, or both. During exercise, tachycardia 
or emotions, myocardial oxygen requirement is increased and if there is coronary obstruction, 
it will lead to a transitory imbalance. This condition is often termed demand ischemia and is 
responsible for most episodes of chronic stable angina. In other conditions, this imbalance 
occurs due to acute decrease of oxygen supply because of increased coronary vascular tone 
(i.e., coronary vasospasm) or obvious reduction or occlusion of coronary artery as a result of 
platelet aggregates or thrombi. This condition which is known as supply ischemia may lead 
to MI and unstable angina (UA). In many conditions, ischemia is a result of both an increase 
in oxygen demand and a reduction in supply [5–8].
The leading cause of MI, by far, is atherosclerosis, a progressive accumulation of cholesterol 
and fibrous tissue in plaques present within the arterial wall, spanning over decades [9–12]. 
Nevertheless atherosclerotic plaques may become unstable, rupture, and form a thrombus 
that occludes the artery. When a significant plaque rupture occurs in the coronary vessels, 
it leads to thrombosis and total vascular occlusion which concludes with the occurrence of 
MI [13, 14].
Total coronary occlusion leading decreased myocardial oxygen supply results with the dam-
age of myocytes [15, 16].
This decreased blood supply has the following consequences:
• After 10–15 min of coronary occlusion necrosis of the myocardial tissue starts and since 
myocardial cells are strongly differentiated cells they have so weak regenerative abilities. 
Thus, according the size of the necrotic tissue the heart becomes a permanently weaker 
pump for the rest of the individual’s life;
• The injured myocardial tissue may cause ventricular arrhythmias (e.g. ventricular tachy-
cardias or ventricular fibrillation) by re-entry mechanism. This is the most common under-
lying mechanism of the sudden cardiac death resulting from MI [17, 18].
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3. Histopathological findings
Examination of the heart shows that there is a well-defined circumscribed area of ischemic 
necrosis (coagulative necrosis). In the first 12–48 h, myocardial fibers are still well delin-
eated with concentrated eosinophilic cytoplasm, but lose their transversal striations and the 
nucleus along with red blood cells which infiltrate the interstitial space. Later (5–10 days after 
the initial event), during healing of the myocardial tissue, the area with coagulative necro-
sis shows histologically preserved myocardial fibers with intensely eosinophilic cytoplasm, 
transverse striations and nuclei which are completely lost. The interstitium of the infarcted 
area is primarily infiltrated with neutrophils, then later with lymphocytes and macrophages 
to phagocytose the necrotic myocyte debris. The necrotic area is peripherally surrounded 
and gradually infiltrated by granulation tissue, which ultimately replace the infarct with a 
fibrous scar [19].
4. Risk factors
Atherosclerotic risk factors are also the most common risk factors for MI. These risk factors 
are old age, obesity, smoking, hypertension, hypercholesterolemia more precisely hyperlipo-
proteinemia particularly high low density lipoprotein (LDL) and low high density lipoprotein 
(HDL), diabetes mellitus [20–23].
Furthermore, intense exertion, especially if the exertion is unusually more intense as com-
pared to the usual performance, and emotional stress are other risk factors. Recent studies 
established that quantitatively, the duration of strenuous exercise and following recovery 
is associated with 6-fold higher MI rate in comparison to the more comfortable time frames 
for people who are physically more fit. For individuals with poor physical health, the rate 
differential is over 35-fold higher. Since the increased arterial pulse pressure results in 
stretching and relaxation of arterial vasculature with each heart beat thereby increasing 
the mechanical stress on atheromas, hence it significantly enhances the susceptibility of 
plaque ruptures [16, 24].
Increased spasm/contraction of coronary artery in association with cocaine abuse can also 
precipitate MI [25–29]. Gender is also another risk factor and male individuals are more prone 
to suffer from MI [30, 31].
5. Diagnosis
The diagnosis of acute MI depends on both clinical and laboratory findings including electro-
cardiogram, and cardiac biomarkers for myocyte injury [32]. Biochemical cardiac markers are 
the signals from the injured myocardium (Figure 1) and are released in case of damage at the 
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cardiac muscle. The most common causes of injury are acute coronary syndromes (MI, non 
Q-wave MI, unstable angina pectoris) and other conditions affecting cardiac muscle includ-
ing trauma, cardiac surgery, myocarditis etc. The level of cardiac biomarkers can be detected/
measured in blood samples in these cases [33–35].
The role of cardiac biomarkers in the process of diagnosis, risk evaluation, and management 
of patients with chest pain has continued to evolve. The initial electrocardiogram (ECG) 
may be non-diagnostic. Although physicians awareness and diagnostic utilities increase the 
rate of missed MI continues to remain between 1.5 and 2%. Determination of cardiac bio-
markers plays an increasingly important role for the evaluation and diagnosis of patients 
with chest pain. The guidelines for the diagnosis of MI have recently been upgraded and 
have incorporated the results of cardiac marker estimation in the clinical definition of MI 
[36–39]. Creatine kinase-MB (CK-MB), cardiac troponin T (cTnT), cardiac troponin I (cTnI), 
myoglobin, homocysteine and C-reactive protein (CRP) are all used for evaluation of the 
suspected acute MI. CK-MB, cTnT, and cTnI may also be used to detect and manage high-
risk patients [36–39].
In early 1990s, the diagnosis of MI was primarily based on an elevated serum CK-MB level. 
Though, the introduction of troponin markers significantly increased the sensitivity and 
specificity for the diagnosis of myocardial injury and for this reason succeeded CK-MB as 
the gold standard for the diagnosis. A consensus guideline from both the American College 
of Cardiology (ACC) and the European Society of Cardiology (ESC) has redefined acute MI 
[40]. According to these associations, acute MI is now typically termed as a typical rise and 
fall of serum biochemical markers (e.g., Troponin, CK-MB), associated with symptoms of 
ischemic injury, new pathologic Q waves on ECG, ischemic ECG changes (ST-segment ele-
vation or depression), coronary artery intervention or histologic findings of AMI [41, 42].
Figure 1. Cardiac muscle cell. Biochemical markers (troponin T, CK-MB, and myoglobin) in myocardium; adopted by 
Cummins.
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Patients with elevated cardiac troponin levels but negative CK-MB who were previously diag-
nosed as unstable angina or minor myocardial injury are now re-stratified as non–ST-segment 
elevation MI (NSTEMI) even in the absence of diagnostic ECG changes [43].
5.1. Operational definition for acute myocardial infarction
The term MI should be used when there is evidence of myocardial necrosis in a clinical setting 
consistent with myocardial ischemia. Under these conditions any one of the following criteria 
meets the diagnosis for myocardial infarction:
• Detection of rise and/or fall of cardiac biomarkers (preferably troponin) with at least one 
value above the 99th percentile of the upper reference limit (URL) together with evidence 
of myocardial ischemia with at least one of the following:
• Symptoms of ischemia;
• ECG changes indicative of new ischemia (new ST-T changes or new left bundle branch 
block [LBBB]);
• Development of pathological Q waves in the ECG;
• Imaging evidence of new loss of viable myocardium or new regional wall motion abnor-
mality [43–46].
5.2. Types of myocardial infarctions
The most recent guidelines recognize five distinct types of MI [43–48].
• Type 1: Spontaneous myocardial infarction related to ischemia due to a primary coronary 
event such as plaque erosion and/or rupture, fissuring, or dissection. This would be the 
typical ST elevation or non-ST elevation MI.
• Type 2: Myocardial infarction secondary to ischemia due to either increased oxygen de-
mand or decreased supply, e.g. coronary artery spasm, coronary embolism, anemia, ar-
rhythmias, hypertension, or hypotension.
• Type 3: Sudden unexpected cardiac death, including cardiac arrest, often with symptoms 
suggestive of myocardial ischemia, accompanied by presumably new ST elevation, or new 
LBBB, or evidence of fresh thrombus in a coronary artery by angiography and/or at au-
topsy, but death occurring before blood samples could be obtained, or at a time before the 
appearance of cardiac biomarkers in the blood.
• Type 4: MI associated with percutaneous coronary interventions, and there are two types 
of this category: one associated with the procedure itself, and one associated with subse-
quently verified stent thrombosis.
• Type 5: Myocardial infarction associated with CABG [43–48].
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6. Biochemical markers of myocardial necrosis
Myocardial cell death can be documented by the appearance in the blood of different proteins 
released into the blood circulation from the ischemically injured myocytes: including myo-
globin, cardiac troponin T and I, CK, LDH, besides many others (e.g. heart fatty acid bind-
ing protein). Myocardial infarction is diagnosed when blood levels of sensitive and specific 
cardiac biomarkers such as cardiac troponin or CK-MB are elevated in the clinical setting of 
acute myocardial ischemia [33, 49, 50]. Even though elevated biomarkers reflect myocardial 
damage and necrosis, they do not designate its underlying mechanism. Hence, an elevated 
value in the absence of clinical findings of ischemia triggers a need to search for other causes 
of cardiac damage, for example myocarditis [43, 45, 48].
6.1. Creatine kinase and CK-MB isoenzyme
Creatine kinase is a regulator of high-energy phosphate production, that is utilized in contrac-
tile tissues [51]. In addition it also has a more general role in shuttling high-energy phosphate 
bonds via creatine phosphate from the site of ATP production in the mitochondria to the site 
of utilization within the cytoplasm [51].
Cytoplasmic CK is a dimer, composed of both M and/or B subunits, that produce CK-MM, 
CK-MB and CK-BB iso-enzymes. CK has also a dimeric mitochondrial form consisting of 
both sarcomeric and non-sarcomeric subunits [52]. Mitochondrial CK is unstable in human 
serum, and that’s why it is difficult to measure. CK-MM is the main isoenzyme found in stri-
ated muscle constituting about 97% of the total CK. CK-MB is found principally in cardiac 
muscle comprising approximately 15–40% of the total CK activity, with the remainder being 
CK-BB. CK-BB is the predominant iso-enzyme found in brain, intestinal and urinary systems. 
The skeletal muscle CK-MB produce 2–3% of the total CK activity; the patients with skeletal 
muscle injury may have increased CK and CK-MB levels [53].
The antibodies in turn inhibit M-subunit activity, with remaining enzyme activity being 
derived from B-subunits only; CK-BB is not detectable by activity measurement in serum, 
except the patient has suffered a serious cerebrovascular accident, so the residual activity rep-
resents CK-MB activity. Although antibodies had been developed to the B- and M-subunits of 
CK, it was thought that MB did not have its own unique antigenicity. However, specific anti-
bodies were developed in the mid- 1980s, allowing the development of direct immunological 
assays for CK-MB. Serum total CK activity and CK-MB concentration rise simultaneously 
following myocardial injury [54, 55].
For CK-MB, two forms of the MB iso-enzyme were eventually recognized and isolated from 
plasma; the tissue form is designated CK-MB2; removal of the lysine residue from the car-
boxy terminus of the single M-subunit, catalyzed by the action of carboxypeptidase-N giving 
rise to the CK-MB1 isoform. Elimination of the lysine residue, which is positively charged, 
leaves a more negatively charged isoform thereby leaving a basis for isolation of the iso-
forms by electrophoresis [56]. The B-subunit is not sensitive to enzymic degradation, so only 
two isoforms of CK-MB exist. In normal plasma, CK-MB isoforms exist with each other in 
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balance ratio of 1:1. Release of tissue CK-MB2 increases its fraction in plasma; a change in 
the ratio of CK-MB2:CK-MB1 from 1:1 to 2:1 can be identified using high-voltage gel electro-
phoresis, even though there is no noticeable change in the plasma concentration of CK-MB 
[56, 57]. Significant fluctuations in the ratio of both the isoforms in plasma can be detected 
between 2 and 4 h after myocardial injury. Systematic prospective studies have confirmed 
that CK-MB isoforms act as an early marker of myocardial injury, and have also established a 
CK-MB2:CK-MB1 ratio above 1.5:1 as a diagnostic criterion [57–59]. The isoform ratio returns 
to normal within 18–30 h after injury. It has been proposed that a normal 1:1 isoform ratio in 
a sample collected at least 6 h after an event effectively excludes a diagnosis of myocardial 
infarction. The rapid return to normal values makes the CK-MB isoforms the best available 
laboratory investigation for the confirmation of re-infarction. Unfortunately, the analytical 
procedure used (high-voltage gel electrophoresis) requires specially designed equipment and 
a great deal of technical expertise, and is therefore unfeasible for daily/routine use. CK-MB 
is a sensitive as well as specific marker for myocardial infarction. CK-MB usually becomes 
abnormal 3–4 h after an event of myocardial infarction, peaks in 10–24 h, and returns to nor-
mal within 72 h [60–62].
Besides, skeletal muscle contains trace amounts of CK-MB, so an elevated serum CK-MB may 
be observed in people with severe skeletal muscle damage and/or renal failure. In such cases, 
the CK index that is CK-MB divided by total CK is very useful. If the index is lower than 4%, 
a non-myocardial etiology of a high CK-MB should be suspected [60–62].
6.2. Troponin T
The troponins are regulatory proteins found in both cardiac and skeletal muscles. They have 3 
subunits; troponin I (TnI), troponin T (TnT), and troponin C (TnC). The genes that code for the 
skeletal and cardiac isoforms of troponin C (TnC) are similar. The skeletal and cardiac subforms 
for troponin I (TnI) and troponin T (TnT) are distinct, and immunoassays have been developed 
to distinguish subtypes [63, 64]. Skeletal TnI and TnT are structurally diverse. No cross-reactiv-
ity arises between skeletal and cardiac TnI and TnT with the current assays [63, 64].
Troponin is adhered to the protein tropomyosin and structurally lies within the groove 
between actin filaments in muscular tissue. In a relaxed muscle, tropomyosin blocks the site of 
attachment for the myosin cross-bridge thereby consequently preventing contraction. When 
the muscle cell is triggered to contract by an action potential, calcium channels get open in the 
sarcoplasmic reticulum hence releasing calcium into the sarcoplasm. A portion of this calcium 
gets attach to troponin resulting in conformational change that displaces tropomyosin so that 
the cross bridges can attach to actin and ensue muscle contraction [63, 64].
Troponin can originate from both skeletal and cardiac muscles, but the specific forms of tro-
ponin vary between types of muscle. The main difference is that the TnC in skeletal muscle 
has four binding sites for calcium ion, whereas in cardiac muscle there are only three. The 
process of contraction in both cardiac and skeletal muscles is controlled by variation in the 
intracellular calcium concentration. When calcium level rises the muscles contract, and when 
calcium drops the muscles relax. Smooth muscle does not contain troponin [65].
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Individual subunits play different roles:
• Troponin C binds to calcium ions to create a conformational change in TnI
• Troponin T binds to tropomyosin, interlocking them to constitute a troponin-tropomyosin 
complex
• Troponin I binds to actin in thin myofilaments in order to hold the troponin-tropomyosin 
complex in place [66].
Cardiac troponin T (cTnT) is a cardio-specific, highly sensitive marker for myocardial 
injury. Cardiac troponin T rises approximately 3–4 h after acute myocardial infarction 
(AMI) and may continue up to 2 weeks thereafter [65, 66]. In comparison to ST-elevation 
myocardial infarction (STEMI), the diagnosis of non-ST elevation myocardial infarction 
(NSTEMI) mainly relies upon level of cardiac troponin T [66]. The diagnosis of MI can be 
made when blood levels of cTnT are above the 99th percentile of the accepted limit along 
with an evidence of myocardial ischemia [67]. Cardiac troponin T is an independent prog-
nostic marker which can forecast the near-, mid-, and even long- term outcome of events 
in patients with acute coronary syndrome (ACS). Cardiac troponin T is also ideal marker 
of myocardial injury in the diagnosis and management of non-ST elevation acute coronary 
syndromes [43, 68] (Figure 2).
6.3. Cardiac troponin I
Cardiac troponin I is the contractile part and it is only present inside the myocardium 
[69, 70]. It is a part of the troponin complex (I, T, C) that along with the tropomyosin is 
bound to actin within the thin myofibril filament. cTnI is acquired as free TnI, as well as 
intricated with troponin C with troponin T termed as binary IT or with both the troponin 
C and troponin T where it is called as ternary ITC. Its physiological function is to hinder 
the ATPase activity of the actin-myosin complex during lack of calcium, and thus, to avert 
muscular contraction [71].
Three types of tissue isoforms are found. Fast and slow troponin I (19,800 Da) participating 
in fast and slow twitch skeletal muscle fibers and cTnI (24,000 Da). All the three isoforms of 
troponin I are encoded by the different genes. The human cTnI reveals merely 54 and 52% 
amino acid sequence homology with human slow and fast skeletal troponin I, respectively 
[72]. cTnI specific monoclonal antibody pair is selected. Moreover it is found that skeletal 
muscles do not express cTnI, neither during development nor in response to a stimuli [72]. 
cTnIs can differentiate cardiac and skeletal muscle injuries, and facilitates the diagnosis of 
MI discrete from the skeletal muscle injuries (e.g. rhabdomyolysis, polytraumatism or from 
the non-cardiac surgery) [72–75]. Increased troponin I levels are also determined in unstable 
angina [76] and congestive cardiac failure [77]. In acute MI serum concentrations of both cTnI 
and CK-MB show similar increase and decrease patterns. It is recommended that at least three 
blood samples should be collected during the early triage period [78]. In the cardiac muscles 
the level of cTnI is 13 times more than that of CK-MB. Moreover cTnI does not circulate in the 
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blood in normal circumstances, therefore elevated serum levels of c TnI are more significant 
for the diagnosis of myocardial necrosis [79]. Data obtained from recent studies specify that 
the troponin I concentration can be determined within the first 3–6 h after the onset of chest 
pain. The levels of Troponin I reach the peak level at approximately 12–16 h and remain 
elevated for 4–9 days after acute MI. The time to attain the peak concentration of cTnI was 
found to be more among patients who did not underwent thrombolytic therapy [73, 80, 81].
Recent studies have found that in patients after AMI the predominant form of cTnI exhib-
ited in blood is the binary troponin IC complex with slight concentrations of ternary ITC 
complex, binary IT complex and free cTnI [82–85]. The release pattern of these forms in MI 
is still under investigation. Commercially available laboratory methods can identify com-
plexed and free cTnI subforms [82, 86, 87]. Some of the assays have the same responses to 
different forms of cTnI. The second type may result in over or under estimation of troponin 
I concentrations in complex biological settings. The equimolar binding characterized as the 
ability to determine both the complexed and free cTnI forms uniformly leads to an unbi-
ased estimation of the total cTnI found in the samples from same subject in MI. The Access 
AccuTnI assay identifies the binary troponin IC or IT or ternary troponin ITC complexes and 
free cTnI evenly. The assay detects both the phosphorylated and dephosphorylated forms of 
cTnI complex [88].
The American College of Cardiology (ACC) and the European Society of Cardiology (ESC) 
guidelines advocate that the different laboratories define their own reference range and also 
Figure 2. The troponin regulatory complex; adopted by Roger Cummin.
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an elevated level of cTnI be identified as an amount above the 99th percentile of a normal 
control group, that is, 99th percentile of the upper reference limit [89, 90].
Conversely in patients with unstable angina and acute MI without the evidence of ST segment 
elevation (NSTEMI) the expectation of suffering from an adverse event is reported to be quite 
difficult. The advancement as well as commercialization of more specific and more sensitive 
cardiac troponin I (cTnI) immunoassays have considerably added to the accurate diagnosis of 
MI and to the risk stratification of NSTEMI/UA patients.
The definition of MI was formally redefined in 2000 by the European Society of Cardiology 
and the American College of Cardiology to realign evidence of myocardial injury as defined 
by biomarkers with a particular advocacy on troponin [32]. The 2000/2002 American College 
of Cardiology (ACC) and the American Heart Association (AHA) Guideline Update evoca-
tively advocate to incorporate the estimation of cTnI for the management of AMI patients 
and also for the risk stratification of patients presenting with symptoms suggestive of acute 
coronary syndromes [40, 91]. This definition was updated in 2007 [43] to reflect the progress 
that had been made in understanding assays. It again relied heavily on a definition based on 
troponin. Specifically, with rare exception, the diagnosis cannot be made in the absence of 
elevated biomarkers of cardiac injury [43, 68].
Considering the potential adverse outcomes the estimation of the prognosis should aid clini-
cians in identification and management of high risk patients. Eventually the evaluation of the 
prognosis will be helpful in both the identification of site of care as well as in distinguishing 
patients most likely to get benefit from specific therapeutic interventions.
7. Conclusion
Acute myocardial infarction usually presents with discomfort or chest pain, weakness, sweat-
ing, nausea, vomiting, and arrhythmias. Common risk factors include old age, obesity, smok-
ing, hypertension, hypercholesterolemia and diabetes mellitus. Myocardial ischemia may 
result either from increased demand or decreased supply of oxygen to the myocardium or 
both.
A consensus guideline from both the American College of Cardiology (ACC) and the 
European Society of Cardiology (ESC) has redefined AMI as a typical rise and fall of serum 
biochemical markers (e.g., Troponin, CK-MB), associated with symptoms of ischemic injury, 
new pathologic Q waves on ECG, ischemic ECG changes (ST-segment elevation or depres-
sion), coronary artery intervention or histological findings of AMI.
Biochemical cardiac markers include myoglobin, cardiac troponin T, cardiac troponin I, 
CK-MB, LDH, and many others like ischemia modified albumin, Glycogen phosphorylase BB 
and fatty acid binding protein. Cardiac markers are vital not only from diagnostic but also 
from the prognostic viewpoint.
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